Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $53.00 million
- Book Value:
- Revenue TTM:
- $46.40 million
- Operating Margin TTM:
- Gross Profit TTM:
- $21.35 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Exagen Inc had its IPO on 2019-09-19 under the ticker symbol XGN.
The company operates in the Healthcare sector and Diagnostics & Research industry. Exagen Inc has a staff strength of 199 employees.
Shares of Exagen Inc opened at $3.1 at the start of the last trading session i.e. 2023-06-03.
The stocks traded within a range of $3.07 - $3.17, and closed at $3.09.
This is a -1.9% slip from the previous day's closing price.
A total volume of 5,300 shares were traded at the close of the day’s session.
In the last one week, shares of Exagen Inc have slipped by -1.28%.
Exagen Inc's Key Ratios
Exagen Inc has a market cap of $53.00 million, indicating a price to book ratio of 0.7319 and a price to sales ratio of 0.8912.
In the last 12-months Exagen Inc’s revenue was $46.40 million with a gross profit of $21.35 million and an EBITDA of $-36745000. The EBITDA ratio measures Exagen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Exagen Inc’s operating margin was -83.13% while its return on assets stood at -23.95% with a return of equity of -79.94%.
In Q1, Exagen Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 8%.
Exagen Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Exagen Inc’s profitability.
Exagen Inc stock is trading at a EV to sales ratio of 0.1527 and a EV to EBITDA ratio of -0.192. Its price to sales ratio in the trailing 12-months stood at 0.8912.
Exagen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $79.23 million
- Total Liabilities
- $9.27 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Exagen Inc ended 2023 with $79.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $79.23 million while shareholder equity stood at $35.94 million.
Exagen Inc ended 2023 with $0 in deferred long-term liabilities, $9.27 million in other current liabilities, 17000.00 in common stock, $-263215000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $52.18 million and cash and short-term investments were $52.18 million. The company’s total short-term debt was $1,326,000 while long-term debt stood at $29.09 million.
Exagen Inc’s total current assets stands at $65.72 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $9.30 million compared to accounts payable of $1.88 million and inventory worth $0.
In 2023, Exagen Inc's operating cash flow was $-396000.00 while its capital expenditure stood at $396000.
Comparatively, Exagen Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Exagen Inc stock is currently trading at $3.09 per share. It touched a 52-week high of $8.96 and a 52-week low of $8.96. Analysts tracking the stock have a 12-month average target price of $6.25.
Its 50-day moving average was $2.69 and 200-day moving average was $2.87 The short ratio stood at 1.36 indicating a short percent outstanding of 0%.
Around 2737.6% of the company’s stock are held by insiders while 6134.8% are held by institutions.
Frequently Asked Questions About Exagen Inc
Similar Industry Stocks (Diagnostics & Research)
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient’s blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.